Dejure FR, Butzer J, Lindemann RK, Mardin BR (2020) Exploiting the metabolic dependencies of the broad amino acid transporter SLC6A14. Oncotarget 11, 4490-4503 33400734

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

S65-p - 4E-BP1 (human) ▲

Modsite: FLMECrNsPVtktPP SwissProt Entrez-Gene Orthologous residues 4E‑BP1 (human): S65‑p, 4E‑BP1 (mouse): S64‑p, 4E‑BP1 (rat): S64‑p, 4E‑BP1 (fruit fly): S65‑p, 4E‑BP1 (cow): S65‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  breast cancer, breast adenocarcinoma, breast cancer, triple negative Relevant cell lines - cell types - tissues:  MDA-MB-468 (breast cell) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes amino_acid_starvation decrease methionine-deficient medium no change compared to control amino_acid_starvation SLC6A14 (human) decrease SLC6A14 KO amino_acid_starvation SLC1A5 (human) decrease SLC1A5 KO amino_acid_starvation SLC7A5 (human) decrease SLC7A5 KO

S172-p - AMPKA1 (human) ▲

Modsite: KIADFGLsNMMsDGE SwissProt Entrez-Gene Orthologous residues AMPKA1 (human): S172‑p, AMPKA1 iso2 (human): S187‑p, AMPKA1 (mouse): S172‑p, AMPKA1 (rat): S172‑p, AMPKA1 (fruit fly): S173‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  breast cancer, breast adenocarcinoma, breast cancer, triple negative Relevant cell lines - cell types - tissues:  MDA-MB-468 (breast cell) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes amino_acid_starvation increase methionine-deficient medium increase SLC6A14 (human) decrease SLC6A14 KO increases amino_acid_starvation SLC6A14 (human) inhibit treatment-induced decrease methionine-deficient medium SLC6A14 (human) inhibit treatment-induced decrease SLC7A5 (human) decrease SLC7A5 KO mildly increases SLC1A5 (human) no change compared to control SLC1A5 KO has no effect hypoxia amino_acid_starvation no effect upon treatment-induced increase Downstream Regulation Effect of modification (function):  enzymatic activity, induced Effect of modification (process):  apoptosis, inhibited, carcinogenesis, inhibited

S52-p - eIF2-alpha (human) ▲

Modsite: MILLsELsRRRIRsI SwissProt Entrez-Gene Orthologous residues eIF2‑alpha (human): S52‑p, eIF2‑alpha (mouse): S52‑p, eIF2‑alpha (rat): S52‑p, eIF2‑alpha (rabbit): S51‑p, eIF2‑alpha (fruit fly): S51‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  breast cancer, breast adenocarcinoma, breast cancer, triple negative Relevant cell lines - cell types - tissues:  MDA-MB-468 (breast cell) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes amino_acid_starvation no change compared to control methionine-deficient medium increase a mild increase SLC6A14 (human) no change compared to control SLC6A14 KO has no effect SLC1A5 (human) no change compared to control SLC1A5 KO has no effect SLC7A5 (human) no change compared to control SLC7A5 has no effect